Please ensure Javascript is enabled for purposes of website accessibility
Contact us Contact Us
EN
Home > Featured Products > Oncology Research > Sarcoma

Sarcoma Research Reagents

Sarcomas are a heterogeneous group of mesenchymal malignancies with >70 histological subtypes. Subtype-specific molecular markers — MDM2 amplification (liposarcoma), KIT/PDGFR mutations (GIST), ALK fusions (IMT), and fusion oncogenes (EWSR1, SS18-SSX) — drive diagnosis and targeted therapy. abinScience provides reagents for MDM2, CDK4, PDGFR, KIT, ALK, Vimentin, Desmin, S100, and CD99. RUO

Key Biomarkers & Targets

MDM2 / CDK4
Well-Differentiated Liposarcoma
MDM2 amplification is pathognomonic for WD/DD liposarcoma; CDK4 co-amplified. MDM2 inhibitors in trials. 10 combined products.
Antibodies • Proteins
KIT / PDGFRα
CD117 / GIST Targets
KIT mutations in ~85% of GIST; PDGFRA mutations in ~5–10%. Imatinib targets. Anti-KIT antibodies with FCM validation. 550+ combined products.
Antibodies • Proteins
ALK
Inflammatory Myofibroblastic Tumor
ALK rearrangements define IMT; crizotinib target. 110+ antibodies and recombinant proteins.
Antibodies • Biosimilars
Vimentin / Desmin
Mesenchymal Markers
Vimentin: pan-mesenchymal marker; Desmin: smooth/skeletal muscle differentiation. Essential IHC markers for sarcoma diagnosis. 80+ combined.
Antibodies • Proteins
CD99
MIC2 / Ewing Sarcoma
Membranous CD99 expression characteristic of Ewing sarcoma/PNET. 12 antibodies and recombinant proteins.
Antibodies • Proteins
S100 / CD34
Neural & Vascular Markers
S100 for MPNST/nerve sheath tumors; CD34 for DFSP and solitary fibrous tumor. 220+ combined antibodies.
Antibodies • Proteins • Biosimilars

Why Researchers Choose abinScience for Sarcoma

Subtype-Specific Diagnostic IHCMDM2/CDK4 (liposarcoma), KIT/DOG1 (GIST), CD99 (Ewing), Desmin/myogenin (RMS), S100 (MPNST) — comprehensive sarcoma classification panel.
GIST Targeted Therapy PanelKIT, PDGFRA, and downstream signaling antibodies for studying imatinib/sunitinib/avapritinib response and resistance in GIST.
Checkpoint ImmunotherapyPD-1, PD-L1, CTLA-4 reagents for characterizing immune microenvironment in sarcoma subtypes with emerging immunotherapy activity (UPS, DDLPS, ASPS).
Original Manufacturer PricingDirect-from-manufacturer pricing with no distributor markup. Bulk and custom conjugation options available.

Common Research Applications

  1. GIST molecular characterization: Use KIT/CD117 and PDGFRA antibodies (IHC, WB) to classify GIST and assess target expression for TKI therapy selection and resistance profiling.
  2. Liposarcoma MDM2/CDK4 profiling: Confirm MDM2 amplification by IHC as a diagnostic marker for WD/DD liposarcoma and assess CDK4 for CDK4/6 inhibitor sensitivity studies.
  3. Ewing sarcoma diagnosis: CD99, NKX2-2, and FLI-1 antibodies available for Ewing sarcoma research. See product pages for validated applications.
  4. Sarcoma differential IHC panel: Vimentin, Desmin, S100, CD34, and related antibodies available for sarcoma subtype classification research. See product pages for validated applications.

Documents & QC Data

Download product datasheets, validation images (WB/IHC/IF/FC), CoA, and application protocols on each product page. All data is lot-specific.

FAQs

Which KIT antibodies are best for GIST IHC?

Anti-KIT/CD117 monoclonal clone SAA0043 with FC validation. See product pages for full application details.

Do you carry MDM2 antibodies for liposarcoma diagnosis?

Yes. Anti-MDM2 antibodies available. See product pages for validated applications.

What Ewing sarcoma markers do you offer?

We offer anti-CD99 (membranous pattern), plus antibodies for FLI-1 and NKX2-2 as supporting markers. Recombinant EWSR1 protein is available for fusion gene research.

Do you have reagents for rhabdomyosarcoma?

Yes — we carry Desmin, myogenin, MyoD1, and Vimentin antibodies for rhabdomyosarcoma IHC diagnosis and embryonal vs. alveolar subtype differentiation.

Can I get custom antibodies for novel targets?

Yes — our parent company AtaGenix provides full custom antibody development from immunogen design through hybridoma production and characterization, including targets not yet in our catalog.

703 product results for "Sarcoma"

Options+
Options
Confirm
  • Product types
    0 selected
    Antibodies (154)
    Research Biosimiliar (2)
    Proteins (60)
    Assay Kit (419)
    Research Biosimilar (59)
  • Expression system
    0 selected
    E. coli (37)
    Mammalian Cells (81)
  • Target
    0 selected
    Elezanumab (1)
    Daclizumab (1)
    NP/Nucleoprotein (3)
    MDM2 (4)
    Emibetuzumab (1)
    Secukinumab (2)
    Rafivirumab (1)
    Elotuzumab (1)
    Sarilumab (2)
    Ziltivekimab (1)
    TPP47 (1)
    SS18L1 (1)
    Ontamalimab (1)
    Lexatumumab (1)
    Eculizumab (3)
    Lenzilumab (1)
    Tirzepatide (2)
    CD246/ALK (9)
    Pasotuxizumab (1)
    Semorinemab (1)
    Mirzotamab (1)
    Siltuximab (3)
    VPF (1)
    A29L (6)
    TP53 (1)
    Semaglutide (2)
    Cixutumumab (1)
    Spike glycoprotein (RBD) (1)
    Tislelizumab (1)
    TP53/p53 (16)
    Trastuzumab (2)
    gD/US6 (1)
    EZH2 (3)
    Obinutuzumab (2)
    vegfab (2)
    Ranibizumab (3)
    DLL4 & VEGFA (3)
    Favezelimab (1)
    Meplazumab (1)
    Vibecotamab (1)
    Imalumab (1)
    Zampilimab (1)
    CD79B (2)
    US8/gE (1)
    Sibrotuzumab (1)
    Afutuzumab (1)
    RBD (6)
    p53 (R175H mutation) pHLA Complex (1)
    RBD (Omicron/JN.1) (1)
    Tanezumab (1)
    RBD (WT) (1)
    G/Major surface glycoprotein G (1)
    Carlumab (1)
    Mirikizumab (2)
    CD20/MS4A1 (3)
    Tigatuzumab (1)
    Aflibercept (1)
    Namilumab (1)
    GP/Envelope glycoprotein (4)
    Rosopatamab (2)
    Tilavonemab (1)
    CD117/KIT (24)
    Omburtamab (1)
    VEGFA (41)
    M1R (5)
    Infliximab (2)
    Evolocumab (1)
    Dalotuzumab (1)
    Toripalimab (1)
    Nirsevimab (1)
    Depatuxizumab (1)
    Denosumab (3)
    RICTOR (1)
    Zanidatamab (1)
    MTOR (4)
    Anifrolumab (1)
    Letolizumab (1)
    Varisacumab (1)
    Dupilumab (3)
    Astegolimab (1)
    Exenatide acetate (2)
    TIGAR (1)
    cGMP (1)
    Ipilimumab (2)
    ATRX/RAD54L (3)
    Cetuximab (3)
    Spike glycoprotein E2 (2)
    Simlukafusp Alfa (1)
    PROK1/EG-VEGF (2)
    Enfortumab (1)
    RBD (Delta) (3)
    Ibalizumab (1)
    RBD (Omicron/KP.2) (1)
    Tocilizumab (3)
    Tibulizumab (1)
    Tosatoxumab (1)
    SLITRK5 (1)
    RBD (Alpha) (1)
    Omalizumab (2)
    Cergutuzumab (1)
    N/Nucleoprotein (1)
    Glembatumumab (1)
    Dilpacimab (1)
    Otilimab (1)
    gG/US4 (2)
    Tarextumab (1)
    Zagotenemab (1)
    VEGF (1)
    Alirocumab (1)
    Figitumumab (1)
    EPO/Erythropoietin (1)
    Palivizumab (3)
    Losatuxizumab (1)
    Indatuximab (1)
    Alacizumab (1)
    BSA (1)
    VEGFA & CD279/PD-1 (1)
    RPTOR (1)
    Tremelimumab (1)
    VEGF/ANG-2 (1)
    SLITRK6 (6)
    Andecaliximab (1)
    Vofatamab (1)
    Ivuxolimab (1)
    TGFBR1 (1)
    Suptavumab (1)
    ENPP7 (1)
    Necitumumab (1)
    sCD14 (1)
    Zenocutuzumab (1)
    Spike glycoprotein E1 (2)
    Epcoritamab (1)
    Spike glycoprotein (10)
    Tregalizumab (1)
    CD340/ERBB2 (1)
    DEPTOR (1)
    Vunakizumab (1)
    Mazdutide (2)
    Adalimumab (3)
    RBD (Beta) (1)
    Rituximab (1)
    Labetuzumab (1)
    Balstilimab (1)
    Navicixizumab (1)
    Faricimab (1)
    Natalizumab (2)
    gB/Envelope glycoprotein B (1)
    Frovocimab (1)
    Imlifidase (5)
    Vascular permeability factor (1)
    H3L (3)
    Canakinumab (1)
    Ganitumab (1)
    Pogalizumab (1)
    WRAP53 (1)
    Icrucumab (1)
    Itolizumab (1)
    TP53TG5 (1)
    PD1 / VEGF-A (2)
    RB1CC1 (1)
    Crizanlizumab (1)
    Iscalimab (1)
    Belantamab (1)
    C3 & C4B & VEGFA (1)
    Ramucirumab (1)
    Protein A (1)
    Zalifrelimab (1)
    Bimagrumab (1)
    LAMTOR4 (1)
    Afasevikumab (1)
    Panitumumab (3)
    F/Fusion glycoprotein F0 (5)
    dsRNA (1)
    Glofitamab (1)
    Ianalumab (1)
    Benufutamab (1)
    Spike Protein (Trimer) (2)
    Zanolimumab (1)
    IL1RL1/ST2 (1)
    Lacnotuzumab (1)
    Obiltoxaximab (1)
    RBD (Gamma) (1)
    Cetrelimab (1)
    Atezolizumab (3)
    Nesvacumab (1)
    Milatuzumab (1)
    gE/Envelope glycoprotein E (1)
    Urelumab (1)
    Befovacimab (1)
    CD140a/PDGFRA (21)
    Lodelcizumab (1)
    VEGF-A (1)
    E8L (5)
    Gevokizumab (1)
    Ustekinumab (3)
    Teprotumumab (1)
    Oxelumab (1)
    Tavolimab (1)
    VEGFA & B7-H1 / PD-L1 / CD274 (1)
    Inclacumab (1)
    EML4-ALK (1)
    Teclistamab (1)
    Lorvotuzumab (1)
    p-TP53 (1)
    Lintuzumab (1)
    Ascrinvacumab (1)
    Human β Amyloid (1-42) (1)
    RRM2B (1)
    Farletuzumab (1)
    ACVR1/ALK-2 (6)
    Bimekizumab (1)
    Suvizumab (1)
    Serclutamab (1)
    Guselkumab (3)
    Clazakizumab (1)
    ATP7B (1)
    Amatuximab (1)
    Ibritumomab (1)
    ERAP1 (1)
    NP/Nucleocapsid (5)
    dsDNA (1)
    Tiragolumab (2)
    Retatrutide (1)
    Certolizumab (2)
    RBD (E484K) (1)
    Cabiralizumab (1)
    Nivolumab (3)
    Avelumab (3)
    Vanucizumab (1)
    Sotrovimab (1)
    KITLG/SCF (1)
    gD/Envelope glycoprotein D (1)
    Utomilumab (1)
    Concizumab (1)
    RB1 (2)
    A35R (5)
    B6R/SL-159 (1)
    FGF2/bFGF & VEGFA (1)
    Mirvetuximab (1)
    Lirilumab (1)
    Ieramilimab (1)
    Cusatuzumab (1)
    VEGFB (7)
    Varlilumab (1)
    LAMTOR5/HBXIP (2)
    TP53BP1 (2)
    SS18 (1)
    LAMTOR3 (2)
    MDM4 (1)
    Human β Amyloid (1-40) (1)
    Edrecolomab (1)
    Daratumumab (3)
    PD-L1 & VEGF (1)
    PDL1 & VEGF (1)
    Basiliximab (1)
    SARS-CoV-2 Neutralization Antibody (3)
    Apamistamab (1)
    Ixekizumab (1)
    RBD (Omicron/BA.4/BA.5) (1)
    ACVR1C (1)
    Olokizumab (1)
    TPP15 (1)
    Anetumab (1)
    Mosunetuzumab (1)
    Blosozumab (1)
    Conatumumab (1)
    Eldelumab (1)
    Glycoprotein (5)
    Sacituzumab (1)
    CD140b/PDGFRB (17)
    β-D-Glucan (1)
    Gremubamab (1)
    RBD (Kappa) (1)
    Emactuzumab (1)
    Pembrolizumab (3)
    Durvalumab (3)
    Casirivimab (1)
    Disitamab (1)
    gC/Envelope glycoprotein C (1)
    Marstacimab (1)
    Tezepelumab (1)
    IL6 (1)
    VEGFA & ANGPT2/ANG-2 (1)
    Bevacizumab (3)
    ACVR1B (1)
    Vorsetuzumab (1)
    cAMP (1)
    PD-L1 / VEGF-A (1)
    Olaratumab (1)
    VEGFA & ANG-2 (3)
    Tisotumab (1)
    ACVRL1/ALK-1 & VEGFA (1)
    Oleclumab (1)
    Cinpanemab (1)
    TAU pT181 (1)
    VEGFC (2)
    Etanercept (3)
    Camidanlumab (1)
    RBD (Omicron/BA.5) (3)
    Remtolumab (1)
    Foravirumab (1)
    Tesidolumab (1)
    Sirukumab (1)
    TPP17 (1)
    Ocaratuzumab (1)
    PDGFC (5)
    Romosozumab (1)
    CDK4 (2)
    CXCL17/DMC/VCC1 (1)
    Drozitumab (1)
    Romiplostim (2)
    M/Matrix protein (2)
    CD292/BMPR1A (7)
    Enoblituzumab (1)
    Vascular endothelial growth factor A (1)
    Golimumab (3)
    RBD (Delta Plus) (1)
    EWSR1 (2)
    Sintilimab (1)
    Pacmilimab (1)
    Lupartumab (1)
    Imdevimab (1)
    Pertuzumab (3)
    gC/UL44 (1)
    Magrolimab (1)
    ACVRL1/ALK-1 (18)
    TRIAP1 (1)
    Brolucizumab (1)
    VEGF-C/VEGF-D (1)
    Codrituzumab (1)
    Glycoprotein G (2)
    Mavezelimab (1)
    Tovetumab (1)
    Talacotuzumab (1)
    CD274/PD-L1 & VEGFA (1)
    TAU pT217 (1)
    Rolinsatamab (1)
    Ifabotuzumab (1)
  • Species
    0 selected
    Rat (1)
    Mus musculus (Mouse) (1)
    Zebrafish (1)
    Felis catus (Cat) (4)
    Homo sapiens (Human) (9)
    Canis lupus familiaris (1)
    Human (88)
    Canis lupus familiaris (Dog) (6)
    Mouse (10)
  • Applications
    0 selected
    Research in vivo (61)
    IF (7)
    Neutralization (1)
    FCM (82)
    ELISA (657)
    Blocking (2)
    IP (3)
    IHC (56)
    RIA (1)
    WB (124)
    SPR (2)
    SDS-PAGE (60)
    Research in vivo (4)
    Immunogen (60)
    Bioactivity: FACS (55)
    Bioactivity testing in progress (38)
    FACS (6)
    Functional assay (61)
    Functional assay (6)
    FuncS (1)
  • Reactivity
    0 selected
    Capra hircus (1)
    Macaca fuscata fuscata (1)
    Pagrus major (1)
    Pig (3)
    Mouse (43)
    Macaca mulatta (1)
    Ovis aries (2)
    Taeniopygia guttata (1)
    Rat (21)
    Marmota monax (1)
    Dog (2)
    Tetraodon nigroviridis (1)
    Rabbit (2)
    Oryctolagus cuniculus (1)
    Xenopus laevis (1)
    Tupaia belangeri (1)
    Bovine (1)
    Chlorocebus aethiops (1)
    Human (129)
    Homo sapiens (Human) (5)
    Pongo abelii (2)
    Equus asinus (1)
    Bos taurus (4)
    Danio rerio (2)
    Macaca fascicularis (2)
    Callithrix jacchus (1)
    Chicken (1)
  • Host species
    0 selected
    Humanized (12)
    Rat (6)
    Human (75)
    Chimeric (1)
    Rabbit (47)
    Mouse (71)
  • Clonality
    0 selected
    Monoclonal (164)
    Polyclonal (47)
  • Conjugate
    0 selected
    FITC (16)
    APC (16)
    PerCP (16)
    PE (16)
    Unconjugated (108)

Quick access

Contact Us

  • +86-27-65523339

  • info@abinscience.com

  • Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China

  • linkedin
  • Ins
  • youtube
  • youtube
Copyright © 2026 abinScience. All Rights Reserved. All Products are for Research Use Only